Santhera, Takeda deal
Santhera said it regained from Takeda exclusive, European and Swiss marketing rights to Catena idebenone for Duchenne muscular dystrophy (DMD), which Santhera granted Takeda in a 2007 deal. The companies also terminated a 2005 deal granting Takeda exclusive, EU and Swiss marketing rights to Catena to treat Friedreich's ataxia (FRDA). Santhera said it approached Takeda to license back the rights "to increase strategic flexibility" after having discussions with third parties who were interested in obtaining worldwide marketing rights to the ubiquinone analog.
Takeda is now eligible to receive a percentage of future income up to €7 million ($9.3 million) generated by Santhera in DMD. Takeda is also eligible to receive €1 million ($1.3 million) as a percentage of Santhera's future income in exchange for terminating the FRDA deal. ...